- Home
- OPRT vs IKT Comparison
OPRT vs IKT Comparison
Compare OPRT & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPRT | IKT |
|---|---|---|
| Founded | 2005 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.8M | 181.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OPRT | IKT |
|---|---|---|
| Price | $5.49 | $1.61 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $5.50 | $4.00 |
| AVG Volume (30 Days) | 316.9K | ★ 499.5K |
| Earning Date | 02-11-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $712,623,000.00 | N/A |
| Revenue This Year | $27.11 | N/A |
| Revenue Next Year | $4.26 | N/A |
| P/E Ratio | $8.27 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.45 | $1.33 |
| 52 Week High | $9.25 | $3.49 |
Technical Indicators
Market Signals| Indicator | OPRT | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 53.18 |
| Support Level | $5.33 | $1.52 |
| Resistance Level | $5.70 | $1.79 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 52.63 | 49.38 |
Price Performance
Historical ComparisonAbout OPRT Oportun Financial Corporation
Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.